M Fabbri1,2, M Zibetti2, L Beccaria2, A Merola3, A Romagnolo2, E Montanaro2, J J Ferreira1,4, S Palermo5, L Lopiano2. 1. Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal. 2. Department of Neuroscience 'Rita Levi Montalcini', University of Torino, Turin, Italy. 3. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USA. 4. Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal. 5. Department of Psychology, University of Turin, Turin, Italy.
Abstract
BACKGROUND AND PURPOSE: Weight loss (WL) is a frequent yet under-recognized complication of levodopa/carbidopa intestinal gel (LCIG) infusion, as well as a milestone of Parkinson's disease (PD) disability progression. The complex association between WL, poor nutritional status, motor complications and PD progression, however, remains unclear. METHODS: Consecutive consenting patients with PD treated with LCIG (n = 44; PD duration, 18.3 ± 6.5 years) were enrolled in an open-label observational study assessing the extent of WL occurring during LCIG treatment. As secondary aims, we correlated the nutritional status, as detected by the Mini Nutritional Assessment, with the severity of motor symptoms [Movement Disorder Society Unified Parkinson's Disease Rating Scale part III], motor complications (Unified Parkinson's Disease Rating Scale part IV), activities of daily living (Schwab and England scale), cognitive impairment (Mini Mental State Examination), depression (Beck Depression Inventory), difficulties in feeding (Edinburgh Feeding Evaluation in Dementia Questionnaire) and levodopa equivalent daily dose (LEDD). RESULTS: There was an average WL of 9.9 ± 10.5% (7.6 ± 7.1 kg) over an LCIG treatment period of 51.6 ± 28.5 months. The extent of WL correlated with the percentage of the waking day spent with dyskinesia (P < 0.05). The nutritional status correlated with motor symptom severity (P < 0.01), dysphagia (P < 0.01) and LEDD (P < 0.01). CONCLUSIONS: Weight loss may occur in patients with PD undergoing LCIG in correlation with the percentage of the waking day spent with dyskinesia. Regardless of the extent of WL, the nutritional status correlated with higher LEDD, as well as with indices of disease progression, such as motor symptom severity and dysphagia.
BACKGROUND AND PURPOSE:Weight loss (WL) is a frequent yet under-recognized complication of levodopa/carbidopa intestinal gel (LCIG) infusion, as well as a milestone of Parkinson's disease (PD) disability progression. The complex association between WL, poor nutritional status, motor complications and PD progression, however, remains unclear. METHODS: Consecutive consenting patients with PD treated with LCIG (n = 44; PD duration, 18.3 ± 6.5 years) were enrolled in an open-label observational study assessing the extent of WL occurring during LCIG treatment. As secondary aims, we correlated the nutritional status, as detected by the Mini Nutritional Assessment, with the severity of motor symptoms [Movement Disorder Society Unified Parkinson's Disease Rating Scale part III], motor complications (Unified Parkinson's Disease Rating Scale part IV), activities of daily living (Schwab and England scale), cognitive impairment (Mini Mental State Examination), depression (Beck Depression Inventory), difficulties in feeding (Edinburgh Feeding Evaluation in Dementia Questionnaire) and levodopa equivalent daily dose (LEDD). RESULTS: There was an average WL of 9.9 ± 10.5% (7.6 ± 7.1 kg) over an LCIG treatment period of 51.6 ± 28.5 months. The extent of WL correlated with the percentage of the waking day spent with dyskinesia (P < 0.05). The nutritional status correlated with motor symptom severity (P < 0.01), dysphagia (P < 0.01) and LEDD (P < 0.01). CONCLUSIONS:Weight loss may occur in patients with PD undergoing LCIG in correlation with the percentage of the waking day spent with dyskinesia. Regardless of the extent of WL, the nutritional status correlated with higher LEDD, as well as with indices of disease progression, such as motor symptom severity and dysphagia.
Authors: Michal Lubomski; Xiangnan Xu; Andrew J Holmes; Samuel Muller; Jean Y H Yang; Ryan L Davis; Carolyn M Sue Journal: Front Aging Neurosci Date: 2022-05-17 Impact factor: 5.702
Authors: Sandeep Thakkar; Victor S C Fung; Aristide Merola; Meredith Rollins; Michael J Soileau; Norbert Kovács Journal: CNS Drugs Date: 2021-02-13 Impact factor: 5.749
Authors: David G Standaert; Jason Aldred; Marieta Anca-Herschkovitsch; Paul Bourgeois; Esther Cubo; Thomas L Davis; Robert Iansek; Norbert Kovács; Francesco E Pontieri; Mustafa S Siddiqui; Mihaela Simu; Lars Bergmann; Pavnit Kukreja; Weining Z Robieson; K Ray Chaudhuri Journal: Mov Disord Clin Pract Date: 2021-09-12
Authors: K Amande M Pauls; Jussi Toppila; Maija Koivu; Johanna Eerola-Rautio; Marianne Udd; Eero Pekkonen Journal: Brain Behav Date: 2021-11-10 Impact factor: 2.708